GlassScriptPhysician profile
Debopam Samanta
NPI 1336393784
$21,276.08
in general payments reported to CMS, 2019-2025
12 companies · $1,338 in 2025
The $1,338 reported for 2025 was more than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
See the full distribution for Neurology with Special Qualifications in Child Neurology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $653 · 2020: $1,100 · 2022: $3,101 · 2023: $12K · 2024: $3,541 · 2025: $1,338.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $11K · Travel and Lodging: $3,763 · Honoraria: $1,290 · Food and Beverage: $797.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $10,572.00 |
| Travel and Lodging | $3,763.41 |
| Honoraria | $1,290.00 |
| Food and Beverage | $796.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $7,780.66 | 2022-2023 | |
| Neurelis, INC. | $6,210.77 | 2023 | Valtoco |
| H. Lundbeck A S | $1,383.01 | 2024 | |
| Neuropace, INC. | $1,370.46 | 2023-2024 | |
| Otter Pharmaceuticals, LLC | $1,338.00 | 2025 | Sympazan |
| Nobelpharma America, LLC | $1,290.00 | 2024 | |
| Zogenix INC. | $1,100.00 | 2020 | |
| Biogen, INC. | $550.15 | 2019 | |
| Cadwell Industries, INC | $150.00 | 2024 | |
| Biocodex, INC. | $103.03 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debopam Samanta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.